InMed Pharmaceuticals Inc

InMed Pharmaceuticals Announces Transition to a Single Cannabinoid Investigational Drug Candidate – INM-755 – for its Epidermolysis Bullosa Program

Transition to INM-755 Expected to Improve the Probability of Development and Regulatory Success Initiation of a Phase I Clinical Trial Remains On-track TSX:IN OTCQX:IMLFF VANCOUVER, March 13, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), ... [Read]

InMed Pharmaceuticals to Present at the 31st Annual ROTH Conference on March 19, 2019

Mar 12

VANCOUVER, March 12, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids as well as a R&D pipeline of medications targeting ... [Read]

InMed Pharmaceuticals Appoints Dr. Steven M. Dinh to Scientific Advisory Board

Mar 6

Dinh Fortifies InMed's Development Expertise in Dermatology and Drug Delivery VANCOUVER, March 6, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics ... [Read]

InMed Pharmaceuticals Reports Second Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update

Feb 12

VANCOUVER, Feb. 12, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet ... [Read]

InMed Pharmaceuticals Announces the Appointment of Dr. Sazzad Hossain, PhD, MSc, as a Member of the Scientific Advisory Board and his Retirement as Chief Scientific Officer

Jan 11

VANCOUVER, Jan. 11, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet ... [Read]

InMed Pharmaceuticals to Present at Biotech Showcase 2019 on January 9, 2019

Jan 3

VANCOUVER, Jan. 3, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN) (OTCQX :IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of ... [Read]

InMed Pharmaceuticals Receives Funding from the Government of Canada to Support Development of Novel Cannabinoid Biosynthesis Program

Dec 4

TSX:IN OTCQX:IMLFF VANCOUVER, Dec. 4, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet ... [Read]

InMed Pharmaceuticals to Commence Trading on TSX, Stock Moves Higher

Mar 23 Caroline Harris

The markets are open, and InMed Pharmaceuticals (CNSX:IN) (OTCMKTS:IMLFF) has an obvious edge up on its competitors. The Canadian Cannabis Market: March 23, 2018. Currently, InMed Pharmaceuticals is trading up more than 20% on the ... [Read]